These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 38247282)
1. Effectiveness, safety and cost-effectiveness of sacral neuromodulation for idiopathic slow-transit constipation: a systematic review. Heemskerk SCM; van der Wilt AA; Penninx BMF; Kleijnen J; Melenhorst J; Dirksen CD; Breukink SO Colorectal Dis; 2024 Mar; 26(3):417-427. PubMed ID: 38247282 [TBL] [Abstract][Full Text] [Related]
2. Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis. Heemskerk SCM; Rotteveel AH; Benninga MA; Baeten CIM; Masclee AAM; Melenhorst J; van Kuijk SMJ; Dirksen CD; Breukink SO Int J Colorectal Dis; 2018 Apr; 33(4):493-501. PubMed ID: 29470731 [TBL] [Abstract][Full Text] [Related]
3. Sacral Neuromodulation Versus Conservative Treatment for Refractory Idiopathic Slow-transit Constipation: The Randomized Clinical No.2-Trial. Heemskerk SCM; Dirksen CD; van Kuijk SMJ; Benninga MA; Baeten CIM; Masclee AAM; Melenhorst J; Breukink SO Ann Surg; 2024 May; 279(5):746-754. PubMed ID: 37991178 [TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sacral neuromodulation for chronic refractory constipation in children and adolescents: a Markov model analysis. van der Wilt AA; Groenewoud HHM; Benninga MA; Dirksen CD; Baeten CGMI; Bouvy ND; Melenhorst J; Breukink SO Colorectal Dis; 2017 Nov; 19(11):1013-1023. PubMed ID: 28834055 [TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of intractable constipation treated by sacral neuromodulation: a comparison between children and adults. Janssen PTJ; Meyer YM; Van Kuijk SMJ; Benninga MA; Stassen LPS; Bouvy ND; Melenhorst J; Breukink SO Colorectal Dis; 2018 Feb; 20(2):134-143. PubMed ID: 28782277 [TBL] [Abstract][Full Text] [Related]
10. Sacral neuromodulation for constipation and fecal incontinence in children and adolescents - study protocol of a prospective, randomized trial on the application of invasive vs. non-invasive technique. Besendörfer M; Kirchgatter A; Carbon R; Weiss C; Müller H; Matzel KE; Diez S Trials; 2024 Mar; 25(1):210. PubMed ID: 38515199 [TBL] [Abstract][Full Text] [Related]
11. Noninvasive Sacral Neuromodulation in Children and Adolescents: A Case-Control Study of Patients With Chronic Refractory Constipation. Diez S; Kirchgatter A; Adam D; Füldner A; Müller H; Matzel KE; Besendörfer M Neuromodulation; 2023 Dec; 26(8):1858-1866. PubMed ID: 36207226 [TBL] [Abstract][Full Text] [Related]
12. Sacral nerve stimulation in slow-transit constipation: effectiveness at 5-year follow-up. Schiano di Visconte M; Pasquali A; Cipolat Mis T; Brusciano L; Docimo L; Bellio G Int J Colorectal Dis; 2019 Sep; 34(9):1529-1540. PubMed ID: 31309325 [TBL] [Abstract][Full Text] [Related]
13. Sacral Nerve Stimulation Fails to Offer Long-term Benefit in Patients With Slow-Transit Constipation. Patton V; Stewart P; Lubowski DZ; Cook IJ; Dinning PG Dis Colon Rectum; 2016 Sep; 59(9):878-85. PubMed ID: 27505117 [TBL] [Abstract][Full Text] [Related]
14. Neuromodulation for constipation: sacral and transcutaneous stimulation. van Wunnik BP; Baeten CG; Southwell BR Best Pract Res Clin Gastroenterol; 2011 Feb; 25(1):181-91. PubMed ID: 21382589 [TBL] [Abstract][Full Text] [Related]
15. Short-term effects of magnetic sacral dermatome stimulation for idiopathic slow transit constipation: sham-controlled, cross-over pilot study. Lee KJ; Kim JH; Cho SW J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):47-53. PubMed ID: 16706811 [TBL] [Abstract][Full Text] [Related]
16. Systematic Literature Review and Meta-Analysis of Sacral Neuromodulation (SNM) in Patients with Neurogenic Lower Urinary Tract Dysfunction (nLUTD): Over 20 Years' Experience and Future Directions. van Ophoven A; Engelberg S; Lilley H; Sievert KD Adv Ther; 2021 Apr; 38(4):1987-2006. PubMed ID: 33713279 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750 [TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018 [TBL] [Abstract][Full Text] [Related]
19. Sacral nerve stimulation for intractable constipation. Kamm MA; Dudding TC; Melenhorst J; Jarrett M; Wang Z; Buntzen S; Johansson C; Laurberg S; Rosen H; Vaizey CJ; Matzel K; Baeten C Gut; 2010 Mar; 59(3):333-40. PubMed ID: 20207638 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Arlandis S; Castro D; Errando C; Fernández E; Jiménez M; González P; Crespo C; Staeuble F; Rodríguez JM; Brosa M Value Health; 2011; 14(2):219-28. PubMed ID: 21402292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]